Richard White presents a brief introduction to TB modelling for beginners.
Dick Menzies discusses key issues to consider when modelling latent TB.
Florian Marx proposes the targeting of previously treated individuals for TB control in high burden settings
Tom Wingfield outlines the implications for models when considering catastrophic costs at the patient level.
Rada Savic argues that it is possible to translate quantitative methods from drugs to vaccines.
Rebecca Harris highlights the contribution of modelling towards Target Product Profile development.
Sophie Rhodes describes the use of a mechanistic model to optimise TB vaccine dose selection